Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes (LIRA-Ramadan™)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01917656
First received: July 29, 2013
Last updated: August 18, 2016
Last verified: August 2016

July 29, 2013
August 18, 2016
January 2014
September 2014   (final data collection date for primary outcome measure)
Change in Fructosamine From Start of Ramadan to End of Ramadan [ Time Frame: Day -1, day 29 ] [ Designated as safety issue: No ]
The level of fructosamine in the blood was used to assess the glycaemic control in the patients during the time period described- from start of Ramadan (day -1, visit 8) to end of Ramadan (day 29, visit 12).
Change in Fructosamine From Start of Ramadan to End of Ramadan [ Time Frame: Day -1, day 29 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01917656 on ClinicalTrials.gov Archive Site
  • Fructosamine at End of Ramadan [ Time Frame: Day 29 ] [ Designated as safety issue: No ]
    The fructosamine values at the end of Ramadan (visit 12) were presented
  • Change From Start of Ramadan to End of Ramadan in Fasting Plasma Glucose (FPG) [ Time Frame: Day -1, day 29 ] [ Designated as safety issue: No ]
    The level of FPG in the blood of fasting patients was addressed to monitor glycaemic control during the period described.
  • Change From Baseline to End of Ramadan in Fasting Plasma Glucose [ Time Frame: Baseline, day 29 ] [ Designated as safety issue: No ]
    The changes from baseline measured postbaseline (i.e., the changes measured on visit 8 and 12) entered as the dependent variables, and visit, treatment, country, and the stratification variables were included as fixed factors and the corresponding values for the specific endpoint measured at randomisation as covariate.
  • Change From Baseline to End of Ramadan in Glycosylated Haemoglobin (HbA1c) [ Time Frame: Baseline, day 29 ] [ Designated as safety issue: No ]
    The level of glycosylated haemoglobin in blood was used to assess the glycaemic control of the patients during the time period described.
  • Change From Baseline to End of Ramadan in Body Weight [ Time Frame: Baseline, day 29 ] [ Designated as safety issue: No ]
  • Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol) (ADA Target) [ Time Frame: Visit 14 (4 weeks post Ramadan) ] [ Designated as safety issue: No ]
    Subjects who at end of treatment (Visit 14, 4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol) (ADA target)
  • Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol), and no Confirmed Hypoglycaemic Episodes [ Time Frame: Visit 14 (4 weeks post Ramadan) ] [ Designated as safety issue: No ]
    Subjects who at end of treatment (Visit 14, 4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol) (ADA target)
  • Number of Confirmed Hypoglycaemic Episodes During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period. [ Time Frame: Day -1 to day 29 ] [ Designated as safety issue: No ]
  • Number of Treatment Emergent Adverse Events (TEAEs) During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period. [ Time Frame: Day -1 to day 29 ] [ Designated as safety issue: No ]

    A serious AE was an experience that at any dose resulted in any of the following: Death, a life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, a persistent or significant disability or incapacity, congenital anomaly or birth defect, important medical events.

    Mild - no or transient symptoms, no interference with the subject's daily activities Moderate - marked symptoms, moderate interference with the subject's daily activities Severe - considerable interference with the subject's daily activities, unacceptable

  • Fructosamine at End of Ramadan [ Time Frame: Day 29 ] [ Designated as safety issue: No ]
  • Change From Start of Ramadan to End of Ramadan in Fasting Plasma Glucose (FPG) [ Time Frame: Day -1, day 29 ] [ Designated as safety issue: No ]
  • Change from baseline to end of Ramadan in FPG [ Time Frame: Baseline, day 29 ] [ Designated as safety issue: No ]
  • Change From Baseline to End of Ramadan in Glycosylated Haemoglobin (HbA1c) [ Time Frame: Baseline, day 29 ] [ Designated as safety issue: No ]
  • Change From Baseline to End of Ramadan in Body Weight [ Time Frame: Baseline, day 29 ] [ Designated as safety issue: No ]
  • Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol) (ADA Target) [ Time Frame: Day 29 ] [ Designated as safety issue: No ]
  • Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol), and no Confirmed Hypoglycaemic Episodes [ Time Frame: Day 29 ] [ Designated as safety issue: No ]
  • Number of confirmed hypoglycaemic episodes [ Time Frame: Day -1 to day 29 ] [ Designated as safety issue: No ]
  • Number of treatment emergent adverse events (TEAEs) [ Time Frame: Day -1 to day 29 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes
This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2 diabetes (T2DM).
Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Diabetes
  • Diabetes Mellitus, Type 2
  • Drug: liraglutide
    1.8 mg administered subcutaneously (s.c., under the skin) once daily
  • Drug: metformin
    Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
  • Drug: sulfonylurea
    Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
  • Experimental: Liraglutide+Metformin
    Liraglutide 1.8 mg administered once daily subcutaneously, in combination with pre-trial tablet metformin of unchanged dose.
    Interventions:
    • Drug: liraglutide
    • Drug: metformin
  • Active Comparator: Sulfonylurea and Metformin
    Subjects continued on pre-trial sulfonylurea tablet treatment, in combination with pre-trial tablet metformin of unchanged dose.
    Interventions:
    • Drug: metformin
    • Drug: sulfonylurea
Azar ST, Echtay A, Wan Bebakar WM, Al Araj S, Berrah A, Omar M, Mutha A, Tornøe K, Kaltoft MS, Shehadeh N. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial. Diabetes Obes Metab. 2016 Oct;18(10):1025-33. doi: 10.1111/dom.12733.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
343
September 2014
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • - Subjects diagnosed with T2DM and treated with metformin equal to or above 1000 mg/day and SU (gliclazide, glipizide or glyburide/glibenclamide at maximum tolerated dose (at least half maximum approved dose) or glimepiride at maximum tolerated dose (at least 2 mg/day)), both at a stable dose for at least 90 days prior to screening. Stable is defined as unchanged medication and dose
  • - HbA1c 7.0-10.0% (53- 86 mmol/mol) (both inclusive)
  • - Body Mass Index (BMI) equal to or above 20 kg/m^2
  • - Subjects who have expressed their intention to fast (daytime, i.e. between sunrise and sunset) during Ramadan after receiving medical counselling regarding the risk of fasting

Exclusion Criteria:

  • - Any contraindication for successful and sustained fasting from a medical perspective at the discretion of the investigator (such as acute illness, severe hypoglycaemia within 90 days prior to screening, a history of recurrent hypoglycaemia, hypoglycaemia unawareness, ketoacidosis within 90 days prior to screening, hyperosmolar hyperglycaemic coma within 90 days prior to screening, subjects performing intense physical labour)
  • - Any chronic disorder or severe disease which, in the opinion of the investigator might jeopardise subject's safety or compliance with the protocol
  • - History of chronic pancreatitis or idiopathic acute pancreatitis
  • - Screening calcitonin value equal to or above 50 ng/L
  • - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
  • - Impaired liver function, defined as alanine aminotransferase (ALAT) equal to or above 2.5 times upper normal limit (UNL)
  • - Impaired renal function defined as estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m^2 per Modification of Diet in Renal Disease (MDRD) formula)
  • - Any episode of unstable angina, acute coronary event, cerebral stroke/transient ischemic attack (TIA) or other significant cardiovascular event as judged by the investigator within 90 days prior to screening
  • - Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Algeria,   India,   Israel,   Lebanon,   Malaysia,   South Africa,   United Arab Emirates
 
NCT01917656
NN2211-3987, U1111-1132-9716
No
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP